Monoclonal antibody-based radioimmunoassay compared with conventional enzyme immunoassay in the detection of prostatic acid phosphatase.
Determination of serum prostatic acid phosphatase by a monoclonal antibody-based radioimmunoassay (RIA) was compared to a polyclonal antibody-based enzyme immunoassay (EIA) to study the clinical value of both test systems. The 97.5 percentile of 48 patients with histologically proven benign prostatic hyperplasia (BPH) was chosen as the normal range. The classification of 38 patients with prostatic carcinoma (CaP) stage pT1-3N0-3M0 was performed by radical prostatectomy and/or pelvic lymph node dissection. Elevated prostatic acid phosphatase (PAP) serum concentrations were observed in 1 of 26 patients with CaP stage pT1-3N0M0 by the EIA and in 7 of 12 patients with CaP stage pT1-3N1-3M0 in both assays. Distant metastases observed in 15 patients lead to elevated PAP serum concentrations in 12 patients by the RIA and in 13 patients by the EIA. The correlation coefficient of both test systems was 0.97. These data indicate that the determination of PAP by a monoclonal antibody-based RIA is of no advantage compared to polyclonal antibody-based EIA, though both test systems are suitable for the follow-up of patients with CaP. Early recognition of CaP, however, is not possible by these two test systems. Elevated serum concentrations of PAP in both assays indicated metastatic disease. These findings should be considered if a curative treatment of CaP is planned.